Dr. Scott Gottlieb: Coronavirus plasma treatment might help but 'doesn't look like a home run'
Dr. Scott Gottlieb told CNBC on Monday that the blood plasma treatment for coronavirus patients tat was just granted emergency approval by the Trump administration may be somewhat effective. The Food and Drug Administration announced on Sunday the emergency use authorization for using convalescent plasma to treat coronavirus patients. Convalescent plasma is a century-old treatment that also was used on patients during the 1918 flu pandemic. The convalescent plasma is then given to people with the coronavirus, in hopes of preventing severe illness. "We have a lot of experience using convalescent plasma in the setting of viral infections.
cnbc.comSexual orientation prevents married physicians from rushing to donate plasma after surviving coronavirus
HOLLYWOOD, Fla. – Dr. John Whitehead and his husband, Dr. Alain Ramirez were both diagnosed with the new coronavirus disease in March. But they are unable to donate the convalescent plasma because they are gay and sexually active. Plasma donor creates website to help COVID-19 patients in needGay and bisexual men face U.S. Food and Drug Administration’s blood donation restrictions dating back to the 1980s. According to the Centers for Disease Control and Prevention gay and bisexual men account for about 70% of new HIV infections in the U.S. each year. “We would all like to get our lives back together, but, we have to be safe.”Blood plasma requirements (Local 10 News)
South Florida talent pitches in on worldwide search for coronavirus treatments
Susan Forbes, a spokeswoman for OneBlood, said he was referring to convalescent plasma, which involves collecting blood from recovered COVID-19 patients. The Food and Drug Administration is facilitating access to the plasma for use in patients with serious or immediately life-threatening COVID-19 infections. “We are not using a virus to induce immune response,” said Strbo, a microbiology professor. On March 20, the FDA granted expanded access to Bellerophon Therapeutics Inc., a clinical-stage biotherapeutics company that owns INOpulse, an inhaled nitric oxide delivery system. On Twitter, he refers to himself as a “Nitric Oxide Aficionado.” He is also on the front lines at Jackson Health’s intensive care units.